New study suggests ketamine may be an effective treatment for children with ADNP syndrome
Growth of psychiatric mental health nurse practitioners helped offset drop in psychiatrists treating Medicare patients
6 September 2022Researchers identify multiple causal genes that drive type 2 diabetes risk
6 September 2022New study suggests ketamine may be an effective treatment for children with ADNP syndrome
Results of a small, but unique research study, led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances, suggest that low-dose ketamine is generally safe, well-tolerated and effective to treat clinical symptoms in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.
